Safety of patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.

Trial Profile

Safety of patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Oct 2017 Results (n=1491) assessing serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE, were published in the Rheumatology.
    • 25 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top